Antiretroviral Therapy during the Neonatal Period by Nuttall, JJC
Page 1 of 8 Guidelines
http://www.sajhivmed.org.za doi:10.4102/sajhivmed.v16i1.361
Rationale for initiating combination antiretroviral therapy 
during the neonatal period
Initiation of combination antiretroviral therapy (cART) at 6–9 weeks of age has been shown to 
reduce early infant mortality by 76% and HIV progression by 75% compared with cART deferred 
until clinical or CD4 criteria were met.1 In the landmark Children with HIV Early Antiretroviral 
Therapy (CHER) trial, although the median age of starting cART in the early treatment arm was 
7.4 weeks, one-third (10/30) of the overall mortality in the trial occurred in the early treatment 
arm.1 In another study, 62% of 403 infants who initiated cART at median 8.4 weeks of age already 
had advanced HIV disease (CD4 < 25% or < 1500 cells/mm3 or World Health Organization 
[WHO] Stage 3 or 4) at initiation.2
The above, with other findings describing the benefits of early cART, raise the question of 
whether even earlier cART initiation – immediately after birth or during the neonatal period – 
could further reduce morbidity and mortality rates, and confer greater benefits, particularly for 
infants who acquired HIV infection during the pregnancy and are consequently at highest risk of 
rapid disease progression.3,4,5,6,7 The potential of early neonatal cART initiation in modifying the 
longer-term trajectory of HIV infection in an individual patient and need for lifelong cART is an 
area of intensive research.
The recent shift to targeted HIV polymerase chain reaction (PCR) testing at birth rather than only 
at 6 weeks of age allows for the earliest detection of neonates in whom intrauterine transmission 
of HIV infection has occurred and has opened the door to neonatal cART initiation. Availability 
of validated point-of-care HIV PCR testing will further increase the drive to initiate cART during 
the early neonatal period.
Safety and efficacy data on neonatal cART is currently very limited. There is even less experience 
with treating premature and low birth weight neonates with cART. Uncertainties relate to 
pharmacokinetics (PK), dosing, safety and choice of cART regimen. In addition, timing of the 
transition from prophylactic antiretroviral (ARV) regimens aimed at prevention of transmission 
to cART regimens aimed at long-term treatment requires further investigation.
Outline of pharmacokinetics, dosing and safety of 
antiretrovirals during the neonatal period
Nucleoside reverse transcriptase inhibitors
Abacavir
Despite the South African (SA) ARV treatment guidelines recommendation that Abacavir (ABC) 
should be used in all first-line cART regimens for children, there are insufficient safety data to 
recommend the use of ABC in infants < 3 months old.8 There is also a lack of PK studies to guide 
dosing in this age group.9
Lamivudine
The SA ARV drug dosing chart (2013) recommends a Lamivudine (3TC) dose of 2 mL (20 mg) twice 
daily from 3 kg – 4.9 kg but advises expert consultation for neonates and infants weighing < 3 kg.10 
Although 3TC is not Food and Drug Administration (FDA) approved for use in infants < 3 months of 
age, it has been used and studied in neonates. The recommended dose for neonates (< 4 weeks of age) 
for either prevention of transmission or treatment is 2 mg/kg/dose twice daily. The recommended 
paediatric dose (age ≥ 4 weeks) is 4 mg/kg/dose twice daily to a maximum dose of 150 mg twice 
daily.11 These recommendations are based on population PK analyses in infants < 6 weeks of age.12,13 
The higher WHO dosage recommendations (3 mL [30 mg] twice daily from 3 kg – 4.9 kg) result in 
increased plasma concentrations compared with the 2 mg/kg/dose recommendations and should 
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Lamivudine has generally been associated with minimal 
toxicity in older children and adults but studies suggest 
that haematological toxicity (anaemia, neutropaenia, 
thrombocytopaenia) increases when combined zidovudine 
(AZT)/3TC neonatal prophylaxis is used when compared 
with AZT alone, with increasing numbers of patients 
requiring treatment discontinuation or blood transfusions.16 
Lamivudine may be given without regard to food, and the 
oral solution may be stored at room temperature. Excretion is 
via the renal route, and dose adjustment is required in renal 
insufficiency.11
Stavudine
The recommended dose for neonates from birth to 13 days 
of age is 0.5 mg/kg/dose twice daily and, from 14 days 
onwards, 1 mg/kg/dose twice daily to a maximum of 30 mg 
twice daily.11,17 Dose reduction is recommended if there 
is renal dysfunction. There are no published data to guide 
Stavudine (D4T) dosing in premature neonates.
The oral liquid formulation requires the addition of water 
to powder, has a concentration of 1 mg/mL, requires 
refrigeration and is stable for 30 days.11 An alternative dosing 
method using opened capsules (available as 15 mg, 20 mg 
or 30 mg) with the contents dispersed in a small amount 
of water and the appropriate dose administered via oral 
syringe, has been investigated and plasma exposure shown 
to be equivalent to ingested whole capsules.18 Stavudine is 
no longer included in SA treatment guidelines, and the oral 
liquid formulation is not readily available in the public sector.8
Although there is limited experience in the context of 
neonatal cART, D4T in older infants and children generally 
has minimal short-term toxicity and good efficacy.11 It may 
therefore be a consideration for short-term use in neonatal 
cART when AZT is contraindicated or haematological 
toxicity has occurred. Alternative options for substitution 
of AZT are limited owing to lack of ABC safety and dosing 
information in infants < 3 months of age.
Zidovudine
There is considerable experience with the use of AZT in 
the neonatal period, although mostly for prevention of 
transmission. Although the landmark PACTG 076 study of 
prevention of mother-to-child transmission of HIV (PMTCT) 
used dosing of 2 mg/kg/dose 6 hourly, more recent data 
support twice-daily dosing.19 Current USA guidelines 
recommend a dose of 4 mg/kg/dose twice daily for either 
prevention of transmission (4–6 weeks) or treatment (4 weeks) 
for neonates with gestational age ≥ 35 weeks.11
Western Cape (South Africa) PMTCT guidelines (2014) 
incorporate combination AZT/ Nevirapine (NVP) prophy-
laxis to prevent transmission in high-risk infants and 
recommend a standardised AZT dose according to birth 
weight (> 2 kg: 12 mg 12-hourly; < 2 kg: 4 mg/kg 12-hourly) 
or gestational age (< 35 weeks: 2 mg/kg 12-hourly) 
administered as post-exposure prophylaxis for 4 weeks.20
The SA ARV drug dosing chart (2013) and WHO weight band 
dosing (2010) recommend a dose of 6 mL (60 mg) twice daily 
from 3 kg – 5.9 kg which is equivalent to 10 mg – 20 mg/
kg/dose or 172 mg – 300 mg/m2/dose but advises expert 
consultation for neonates and infants weighing < 3 kg.10,15
It is recognised that the standard paediatric AZT dose 
(240 mg/m2/dose twice daily) may lead to haematological 
toxicity (anaemia, neutropaenia, thrombocytopaenia), 
particularly in premature neonates with anaemia of 
prematurity and where other agents that may cause bone 
marrow suppression (e.g. ganciclovir, co-trimoxazole) are 
administered concurrently. Specific dosing based on PK 
studies in premature neonates is available and close 
monitoring of haematological parameters is recommended (at 
least every 2–4 weeks) during the neonatal and early infant 
period.11,21 Switching from AZT to an alternative medication 
should be considered if signs of haematological or other 
toxicity are severe or persistent. Dosing adjustment is required 
in the setting of renal insufficiency or hepatic impairment.11
An intravenous (IV) AZT formulation is available. It is 
generally used in the setting of prevention of transmission 
when the neonate is unable to tolerate oral medication.11 
As no other IV ARV formulations are available, a fully IV 
treatment regimen is not feasible. Monotherapy with IV AZT 
as treatment in HIV-infected neonates is not recommended.
After 6 weeks of age, AZT dosing according to the SA ARV 
drug dosing chart (2013) is recommended.10 Alternatively, 
body surface area-based dosing (240 mg/m2/dose twice 
daily) may be used.11
Non-nucleoside reverse transcriptase inhibitors
Nevirapine
Although the use of NVP is well established for prevention 
of transmission, the optimal treatment dose for neonates 
< 14 days of age has not been established. The dose of oral 
suspension approved for treatment in neonates > 15 days 
of age and children is 200 mg/m2/dose twice daily with a 
maximum dose of 200 mg (immediate-release formulation) 
twice daily.11
The standard practice of using a 14-day lead-in dose when 
initiating treatment with NVP in order to allow induction of 
cytochrome p450 metabolising enzymes and reduce occurrence 
of rash, can lead to subtherapeutic plasma NVP levels. This 
effect increases the risk of developing drug resistance and 
associated worse virological and clinical outcomes. Initiating 
cART with full-dose twice-daily NVP in black African children 
< 2 years of age without previous NVP exposure resulted 
in fewer subtherapeutic NVP levels than the 14-day dose 
escalation approach, and none of the children less than 2 years 
of age who received full-dose NVP developed rash.22
In HIV-infected neonates who are transitioning from once-
daily NVP prophylaxis for prevention of transmission to cART 
containing NVP, it would seem appropriate to use full-dose 
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NVP with careful clinical and laboratory monitoring from the 
start of cART because some degree of induction of cytochrome 
p450 metabolising enzymes is likely to have already occurred. 
Further studies that include both neonates exposed to NVP 
prophylaxis for prevention of transmission and those without 
previous NVP exposure are required to validate the safety, 
efficacy and feasibility of full-dose NVP initiation. Based on 
PK modelling, the International Maternal Pediatric Adolescent 
AIDS Clinical Trials (IMPAACT) P1115 study will investigate 
a NVP treatment dose of 6 mg/kg/dose twice daily with full-
dose initiation in full-term neonates < 48 hours of age.23
Nevirapine toxicities include rash, hypersensitivity reactions, 
and hepatotoxicity. Close monitoring for rash and liver 
function test abnormalities is required. NVP should not be 
administered to patients with moderate or severe hepatic 
impairment. In addition, drug-drug interactions are common 
and concomitant medications should be carefully reviewed 
prior to initiating NVP.11
Efavirenz, etravirine and rilpivirine are not approved for use 
in neonates and are not recommended.11
Protease inhibitors
Lopinavir/ritonavir
Lopinavir/ritonavir (LPV/r) co-formulated oral solution 
(Kaletra) was first approved by the USA’s FDA in 2000 for 
the treatment of HIV-infected children ≥ 6 months old. In 
2008, Kaletra oral solution was approved for use in children 
≥ 14 days old.24 The recommended dose of oral solution is 
300 mg/m2/dose twice daily.11
In January 2011, the FDA released a statement on Kaletra 
toxicity in neonates.24 Post-marketing cases of toxicity were 
reported to the FDA’s Adverse Event Reporting System 
(AERS) in September 2010 and were attributable to LPV 
and/or the inactive ingredients propylene glycol and 
ethanol. Kaletra oral solution contains 152.7 mg/mL of 
propylene glycol (15.3% w/v) and has a high ethanol content 
(356 mg/mL or 42.4% v/v).
A search of the AERS database revealed 10 reported cases 
with adverse events that might have been related to LPV, 
propylene glycol or ethanol. All 10 patients were neonates, 
and 8 of the 10 were premature neonates. Cardiac toxicity 
occurred in 7 of the patients and included bradycardia, 
sinoatrial block, complete atrioventricular block, congestive 
cardiomyopathy, cardiac failure and cardiogenic shock. An 
elevated lactate level was documented in 2 cases. 
Neuromuscular toxicity in 3 neonates included hypotonia, 
abnormal electroencephalogram (EEG), altered state of 
consciousness, somnolence and asthenia. Acute renal failure 
was seen in 5 neonates and an increased serum creatinine 
was documented in 1. Four neonates developed 
hyperkalaemia. Respiratory complications occurred in 3 
neonates and included respiratory failure, pulmonary 
haemorrhage, respiratory arrest, dyspnoea and wheezing. 
Gastrointestinal events in 5 neonates included vomiting, 
failure to thrive, abdominal distension and ulcerative colitis. 
One of the 10 neonates died.24,25
Eight of the 10 neonates received their first dose of 
Kaletra within the first 2 days of life. The onset of toxicity 
occurred within 1–6 days in 8 of the neonates. A full-term 
infant showed the first signs of toxicity 20 days after birth. 
After Kaletra was discontinued, 6 neonates recovered 
within 5 days.24,25 Transient asymptomatic elevation in 
17-hydroxyprogesterone levels has been reported in term 
neonates treated at birth with LPV/r.26
As an appropriate dose in premature infants and neonates 
< 14 days of age is not known and the consequences of 
Kaletra toxicity in premature infants can be severe or possibly 
fatal, the FDA strongly recommends that Kaletra should be 
avoided in this age group:11,24
If in the judgment of the health care professional, the benefit 
of using Kaletra oral solution in babies to treat HIV infection 
immediately after birth outweighs the potential risks, then the 
neonate should be monitored closely for increases in serum 
osmolality and serum creatinine and for toxicity related to 
Kaletra oral solution. These toxicities include hyperosmolality 
with or without lactic acidosis, renal toxicity, CNS depression 
(including stupor, coma, and apnea), seizures, hypotonia, 
cardiac arrhythmias, ECG changes and hemolysis.24
The IMPAACT P1030 study evaluated PK, safety and efficacy 
of LPV/r 300 mg/m2/dose twice daily in combination with 
2 nucleoside analogues in 10 HIV-infected infants with an 
age range of 3.6–5.9 weeks. Amongst 9 infants completing 
intensive PK evaluation on a median dose of 267 mg/m2/dose 
(range 246–305) twice daily, the LPV area-under-the curve 
(AUC) was significantly lower than that in the 6-weeks to 
6-months of age cohort. The LPV trough level (Cmin) ranged 
from 0.99 µg/mL – 4.87 µg/mL which did not differ from the 
older children. A plasma LPV trough concentration of ≥ 1 µg/mL 
has been used as a correlate of efficacy in treatment-naïve 
adults. After 24 weeks’ follow-up, adverse events were limited 
to transient neutropaenia in 3 infants, and only 2 of 10 infants 
met criteria for protocol-defined virological failure. Noting the 
low LPV exposure (AUC), the authors advised careful dose 
calculation and frequent dose adjustment for weight gain, and 
proposed studying a higher dose for very young infants.27,28
Taking into account the increasing usage of LPV/r 
administration to neonates at risk of perinatal or postnatal 
HIV transmission, Urien et al.29 aimed to determine optimal 
dosing for LPV/r in the first weeks of life based on a population 
PK approach incorporating body weight, gestational age 
and postnatal age in 96 infants from France and the UK. 
Amongst the 96 neonates, 7 were on treatment for neonatal 
HIV infection. The median postnatal age was 2 weeks (range 
1 day – 102 weeks), median gestational age was 38 weeks (range 
27.3–41 weeks), median body weight was 3.3 kg (range 1.16 kg 
– 10.4 kg). A total of 163 LPV concentrations were available 
for analysis. The mean LPV dosage was 590 mg/m2/day 
(range 106–1454) or 39 mg/kg/day (range 11–110) dosed 
between 1 and 3 times per day. A one-compartment model 
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described the data with body weight and age being the main 
influential covariates. The following dosage regimen was 
derived from the predicted LPV trough concentrations using 
a therapeutic range of 1 µg/mL – 8 µg/mL: 40 mg 12-hourly, 
80 mg 12-hourly and 120 mg 12-hourly for 1 kg – 2 kg, 2 kg – 
6 kg and 6 kg – 10 kg groups respectively.29
Holgate et al.30 described the use of Kaletra-based cART in 8 
HIV-infected premature neonates treated between 2006 and 
2011 in Cape Town. The median gestational age at birth was 
31 weeks (range 27–33), median age at initiation of LPV/ 
r-based cART was 26.5 days (range 5–96), median corrected 
gestational age at cART initiation was 34.1 (range 31.6–44.7) 
and median dose of LPV/r at time of measuring LPV levels 
was 287 mg/m2/dose or 23.1 mg/kg (range 235–325; 21.1–
28.6, respectively). LPV trough levels were sampled a median 
7 days after LPV/r initiation, 3 infants had subtherapeutic 
plasma levels (< 1 µg/mL), and in 1 infant the plasma level 
was above the recommended target range (> 4 µg/mL). The 
dose of LPV/r was adjusted in the 3 infants with low levels 
and a median dose of 533 mg/m2 (range 400–540) resulted 
in plasma levels within the recommended therapeutic range. 
Overall, 5/8 infants required doses > 300 mg/m2 to achieve 
plasma LPV trough levels within the recommended range. 
No adverse effects attributable to LPV/r solution were 
observed. The study highlighted the role of therapeutic drug 
monitoring in order to achieve target trough LPV levels. 
Although no toxicity was observed, the authors emphasised 
the need for extreme caution and careful monitoring of 
premature neonates treated with Kaletra.30
Although nelfinavir (NFV) has been used in ART regimens 
for prevention of transmission and treatment, it is not 
currently recommended for treatment in children < 2 years of 
age as there is significant inter-individual variation in plasma 
levels and insufficient PK data to support a standardised 
dosing regimen.11
Atazanavir, darunavir, fosamprenavir, indinavir, full-dose 
ritonavir (RTV), saquinavir and tipranavir are not approved 
for use in neonates and are not recommended.11
Integrase inhibitors
Raltegravir
There are currently no published data on safety and 
dosing of Raltegravir (RAL) in neonates. However, 
Phase 1 and 2 studies are underway. The IMPAACT 
P1097 study investigated washout PK in neonates born 
to HIV-infected mothers and showed that the neonatal 
half-life of RAL varied between 9 and 184 hours, most 
likely owing to reduced capacity for metabolism and 
elimination in newborns.31 The Phase 1 IMPAACT P1110 
trial is investigating the safety and PK of RAL suspension 
(granules for suspension) in HIV-exposed neonates at high 
risk of acquiring HIV infection. Different dosing strategies 
between birth and 6 weeks of age will be investigated with 
the option of continuing RAL beyond 6 weeks of age in 
infants found to be HIV-infected.32
The IMPAACT P1066 study investigated the use of RAL oral 
suspension in combination with an optimised background 
ARV regimen in 26 HIV-infected infants and young children 
aged 4 weeks to 2 years who had previously received ARV 
medication for prevention of perinatal transmission. Clinical 
outcomes were acceptable, there were no treatment 
discontinuations owing to adverse events, and PK parameters 
were similar to those achieved amongst cohorts of older 
children in the same study.33 Raltegravir oral suspension is 
currently approved by the FDA for use in infants > 4 weeks 
of age and > 3 kg body weight.11 In SA, RAL suspension is not 
currently registered by the Medicines Control Council. In the 
SA public sector, RAL has been restricted for use in third-line 
ART regimens.
Dolutegravir and elvitegravir are not approved for use in 
neonates and are not recommended.11
Choice of combination antiretroviral 
therapy regimen in neonates
Current SA HIV treatment guidelines recommend 
ABC+3TC+LPV/r as first-line cART for all HIV-infected 
children < 3 years of age; there are no separate recom-
mendations for full-term or premature neonates.8 There are 
currently no published clinical trial data comparing different 
cART regimens initiated during the neonatal period. Clinical 
trials in older infants and young children have informed 
treatment recommendations in these age groups and are 
important to consider in relation to cART initiation during 
the neonatal period.
The IMPAACT P1060 trial showed that LPV/r-based cART 
was virologically superior to NVP-based cART both in 
infants with previous exposure to NVP (6–36 months of 
age) and in infants without previous exposure to NVP (3–36 
months of age).34,35 One of the reasons proposed to explain 
the difference in virological efficacy between NVP and LPV/r 
is the dose escalation strategy used when initiating NVP, as 
this has been associated with subtherapeutic plasma NVP 
levels which could increase the risk of developing drug 
resistance and treatment failure.22 Initiation of cART with 
full-dose NVP has been investigated and further studies are 
underway.22,23
An additional possible explanation for the difference in 
outcomes relates to the presence of drug resistance mutations 
prior to cART initiation. In settings of high nucleoside reverse 
transcriptase inhibitor (NRTI) exposure owing to the use of 
NVP for prevention of transmission and use of NRTI/ Non-
nucleoside reverse transcriptase inhibitor (NNRTI) regimens 
during pregnancy, the presence of resistance mutations 
may compromise the efficacy of NVP-based regimens in 
the neonate. HIV drug resistance mutations in plasma 
virus were determined using population sequencing in 230 
newly-diagnosed HIV-infected children < 2 years of age in 
Johannesburg in 2011. Two-thirds of the HIV-infected children 
had been exposed to maternal and/or infant PMTCT, 56.8% 
had NNRTI, 14.8% NRTI and 1.3% PI mutations. In children 
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with no reported PMTCT exposure, resistance to NNRTI was 
detected in 24%, to NRTI in 10.7% and to PI in 1.3%. In the 
children who were tested at ≤ 8 weeks of age, 85% had NNRTI 
drug resistant mutations present.36
The above data support the use of PI-based first-line cART 
in HIV-infected infants and young children regardless of 
PMTCT history. However, owing to potentially severe and 
life-threatening short-term toxicity concerns, Kaletra is 
currently not recommended in neonates < 14 days old and 
< 42 weeks corrected gestational age. Long-term toxicities of 
PIs, including effects on growth and lipid metabolism, have 
also been reported.37,38
Other studies have investigated whether 4 rather than 3 ARV 
drugs could improve outcomes based on the observation that 
young infants commonly have very high HIV viral loads and 
the hypothesis that increased regimen potency might achieve 
more rapid virological suppression, immunological recovery 
and better long-term treatment efficacy. However, the 
available studies are heterogeneous in nature and therefore 
difficult to compare directly, and 3 drug regimens have 
remained the standard-of-care in most guidelines.
The PACTG 356 study showed superior virological suppression 
rates of a 4-drug regimen comprising D4T/3TC/NVP/NFV 
compared with either AZT/3TC/ABC/NVP or AZT/3TC/
NVP.39 Prendergast et al.40 showed that infants randomised to 
receive immediate or deferred (until CD4 count reached < 
20%) 4-drug cART comprising AZT/3TC/NFV/NVP were 
able to achieve excellent adherence and virological suppression 
after one year by intention-to-treat analysis of 80%. The 
European Pregnancy and Pediatric HIV Cohort Collaboration 
(EPPICC) observational study of 437 infants initiating cART 
during the first year of life showed better virological and 
immunological responses among those starting 4-drug 
NNRTI-based regimens than 3-drug NNRTI-based and LPV/
r-based regimens after median 5.9 years of follow-up.41 The 
AntiRetroviral Research for Watoto (ARROW) trial conducted 
among 3-month – 17-year-old children in Uganda and 
Zimbabwe showed no long-term (72 weeks) immunological 
benefit to starting 4-drug cART (NNRTI +3 NRTIs) then 
simplifying to 3-drug cART (either NNRTI + 2 NRTIs, or 3 
NRTIs) compared with starting 3-drug cART (NNRTI + 2 
NRTIs), and there was increased toxicity with 4-drug cART.42
Further clinical trials comparing safety, tolerability and 
efficacy of different cART regimens, including consideration 
of 4-drug and triple class regimens, initiated during the 
neonatal period in high burden settings are warranted in 
order to better guide treatment recommendations.
Transition from antiretroviral 
prophylaxis to treatment
Neonatal ARV prophylaxis regimens vary between 
guidelines. In SA, prophylaxis regimens include NVP 
alone, AZT alone, NVP + AZT, and NVP + AZT + 3TC, and 
recommended duration ranges from 6 weeks to 3 months or 
more.8,43 As a result, most neonates will be receiving ARV 
prophylaxis at the time that a positive birth HIV PCR test 
result is obtained.
Transition from neonatal ARV prophylaxis to neonatal 
cART requires adjustment to the number and choice of 
ARVs, dosage and dose frequency in most cases. Clinical 
assessment of the neonate, baseline investigations and careful 
counselling of the mother and family are pre-requisites to 
cART initiation. Although optimal strategies for transition 
from prophylaxis to cART have not been widely studied, 
it is recommended that a standardised approach applicable 
to the majority of HIV-infected neonates is adopted 
(Figure 1). Expert opinion and individualised guidance 
will still be required for certain categories of neonates; for 
example, low birth weight, premature or unwell neonates.
After obtaining a positive HIV PCR test result in a neonate, 
the following actions are required prior to consideration of 
cART initiation:
• A blood sample for confirmatory viral detection assay 
(second HIV DNA PCR test as per current National 
Department of Health [NDOH] SA guidelines or HIV 
RNA/viral load) must be submitted to the laboratory.8,43 
Initiation of cART should not be delayed on the basis 
that the result of the confirmatory PCR test has not yet 
been obtained. Rapid and systematic follow-up of birth 
HIV PCR tests that might have been submitted to the 
laboratory by the birthing facility or a referring clinic or 
hospital, and recall of HIV-positive neonates, is essential.
• The clinical condition of the neonate must be assessed. 
This includes determining the corrected gestational 
age (in weeks), postnatal age, birth weight and current 
weight, presence of any vital organ dysfunction 
including neonatal jaundice, hepatitis or renal 
dysfunction, and presence of other congenital or acquired 
infections including syphilis, tuberculosis (TB) and 
cytomegalovirus as indicated by the maternal history 
and clinical state of the neonate. Co-morbidities and their 
treatment may alter the timing of cART initiation and the 
treatment regimen required in the neonate. In neonates 
who are clinically unstable at the time that HIV infection 
is diagnosed, ARV prophylaxis should be discontinued 
and the neonate stabilised and treated as necessary prior 
to initiation of cART. In addition, neonates who are not 
fully established on enteral feeding are not eligible to 
initiate cART.
  HIV-infected neonates who are also exposed to and/
or infected with TB require evaluation as to the 
infectiousness and drug sensitivity profile of the 
contact, and assessment (clinical, radiological, 
bacteriological) of TB infection/disease followed by 
anti-TB chemoprophylaxis or treatment. HIV-infected 
neonates initiated on rifampicin and receiving LPV/
r-based cART will require additional RTV (0.75 x LPV 
dose) to be added to the cART regimen although PK, 
safety and efficacy data for the super-boosting 
strategy in the neonatal age group is lacking. The PK, 
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safety and efficacy of rifampicin in combination with 
NVP-based cART in the neonatal age group is also 
not known. Expert advice should be obtained.
• Baseline blood investigations should be performed 
including full blood count and differential white cell 
count, urea and creatinine, and alanine aminotransferase 
(ALT).
• Careful and detailed counselling of the mother and if 
possible other family members who will be involved in the 
care of the neonate is required. The mother of the child 
might not have disclosed her own HIV status to other 
family members, and disclosure of the neonate’s HIV 
status to the family should be discussed. In addition to 
providing support, counselling should include information 
about the HIV diagnosis in the neonate as well as details 
about cART. Information and guidance on infant feeding 
should be provided. Mothers who had chosen to breastfeed 
should be encouraged to continue breastfeeding whilst 
mothers who had chosen formula feeding should consider 
switching to breastfeeding if feasible.
• Ideally, a blood sample should be submitted for ARV drug 
resistance testing (genotyping) prior to initiation of cART in 
the neonate. This is particularly relevant when the neonate 
has been exposed to maternal cART or ARV prophylaxis 
prior to the diagnosis of HIV infection, and may assist in 
determining optimal ARV drug choices in future cART 
regimens for the child. Expert advice should be obtained 
to assist in the management of HIV-infected neonates born 
to mothers on 2nd- or 3rd-line cART regimens.
In neonates ≥ 15 days of age and ≥ 42 weeks corrected 
gestational age and with normal renal and hepatic function, 
an initial regimen of AZT+3TC+LPV/r is recommended. 
Refer to Table 1 and Figure 1 for guidance on dosing and 
monitoring.
In full-term neonates ≤ 14 days of age, approved dosing 
recommendations are only available for AZT and 3TC. 
Treatment with only 2 drugs is not recommended. Based on a 
detailed review of available PK data, an NVP dose of 6 mg/
kg/dose twice daily in full-term neonates initiating cART < 
48 hours of age is under investigation in the IMPAACT P1115 
study. Pending the results of this and other studies, a provisional 
recommendation to use an initial regimen of AZT+3TC+NVP 
dosed twice daily in neonates ≥ 35 weeks gestational age at 
birth, regardless of postnatal age, with normal hepatic function 
and appropriate monitoring for toxicity seems reasonable. Refer 
to Table 1 and Figure 1 for guidance on dosing and monitoring. 
As there are data for older infants and young children showing 
superior efficacy of LPV/r-based, compared with NNRTI-
based, cART, these neonates should be considered for elective 
switch to AZT+3TC+LPV/r when they are ≥ 15 days of age and 
≥ 42 weeks corrected gestational age.
The decision to initiate cART in premature neonates 
< 35 weeks gestational age involves assessing the relative risks 
and benefits of using unapproved dosing and the inherent 
concerns regarding drug toxicity. Dosing recommendations 
for premature neonates are currently only available for AZT. 
Treatment with AZT alone is not recommended and, based 
on currently available data, it is recommended that Kaletra 
should be avoided in this age group (refer to Table 2). 
TABLE 1: Antiretroviral drugs, formulations and dose recommendations for treatment of full-term neonates. 
Inhibitor ARV drug Formulations Dose Comment
Nucleoside reverse 
transcriptase Inhibitors 
Abacavir 20 mg/mL Neonatal dose not known Not FDA approved for infants  
< 3 months of age
Lamivudine 10 mg/mL Birth – 4 weeks of age: 2 mg/kg/dose twice daily
≥ 4 weeks of age:
•  If < 3 kg body weight: 4 mg/kg/dose twice daily
•  If ≥ 3 kg body weight: may be dosed according to 
SA ARV dosing chart
Not FDA approved for infants 
< 3 months of age but generally 
well tolerated. May contribute to 
haematological toxicity
Stavudine Oral suspension: powder for 
reconstitution with water 
1 mg/mL; Capsules: 15 mg, 
20 mg, 30 mg
Birth – 13 days of age: 0.5 mg/kg/dose twice daily
≥ 14 days of age: 1 mg/kg/dose twice daily
Consider use if AZT contraindicated or 
haematological toxicity
Reconstituted oral suspension: requires 
refrigeration, stable for 30 days, no 
longer readily available
Capsules may be opened, contents 
dispersed in water and appropriate dose 
administered
Zidovudine 10 mg/mL Birth – < 4 weeks of age (≥ 35 weeks gestational age): 
4 mg/kg/dose twice daily 
≥ 4 weeks of age: 
•  If < 3 kg body weight: 12 mg/kg/dose twice daily 
or 240 mg/m2/dose twice daily 
•  If ≥ 3 kg body weight: may be dosed according to 
SA ARV dosing chart 
Monitor for haematological toxicity
Non-nucleoside reverse 
transcriptase inhibitor 
Nevirapine 10 mg/mL ≤ 14 days of age: treatment dose is undetermined
Investigational dose (IMPAACT P1115): 6 mg/kg/dose 
twice daily ≥ 15 days of age:
• If < 3 kg body weight: 200 mg/m2/dose twice daily
•  If ≥ 3 kg body weight: may be dosed according to 
SA ARV dosing chart
Monitor for rash, hypersensitivity 
reactions, hepatotoxicity
Protease inhibitor Lopinavir/ ritonavir 
(Kaletra)
80 mg/20 mg LPV/r per 
1 mL
300 mg/m2/dose twice daily
Doses may require adjustment based on therapeutic 
drug monitoring, if available
Contraindicated < 14 days of age and 
< 42 weeks corrected gestational age
Refer to text for details on monitoring 
required
Source: Adapted from Ref. 11
Note: Body surface area (m2) = (0.05 x weight [kg]) + 0.05.
ARV, antiretroviral; LPV/r, Lopinavir/ritonavir; SA ARV, South African antiretroviral; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical Trials; FDA, Food and Drug Administration; 
AZT, zidovudine. 
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Abacavir 20 mg/mL Appropriate dose for treatment of premature  
neonates is not known
Not FDA approved for infants < 3 months  
of age
Lamivudine 10 mg/mL Appropriate dose for treatment of premature  
neonates is not known
Not FDA approved for infants < 3 months  
of age but generally well tolerated. May  
contribute to haematological toxicity
Stavudine Oral suspension: powder for 
reconstitution with water  
1 mg/mL; Capsules: 15 mg, 
20 mg, 30 mg
Appropriate dose for treatment of premature  
neonates is not known
Reconstituted oral suspension: requires  
refrigeration, stable for 30 days, no longer  
readily available
Capsules may be opened, contents  
dispersed in water and appropriate dose  
administered
Zidovudine 10 mg/mL •  ≥ 35 weeks gestation: 
birth – < 4 weeks of age: 4 mg/kg/dose twice daily 
≥ 4 weeks of age: 
If < 3 kg body weight: 12 mg/kg/dose twice daily or  
240 mg/m2/dose twice daily 
If ≥ 3 kg body weight: may be dosed according to SA  
ARV dosing chart 
• ≥ 30 to < 35 weeks gestation: 
birth – < 2 weeks of age: 2 mg/kg/dose twice daily 
≥ 2 weeks – < 8 weeks of age: 3 mg/kg/dose twice daily
≥ 8 weeks of age: 12 mg/kg/dose twice daily 
• < 30 weeks gestation: 
birth – < 4 weeks of age: 2 mg/kg/ dose twice daily 
≥ 4 weeks – < 10 weeks: 3 mg/kg/dose twice daily 
≥ 10 weeks of age: 12 mg/kg/dose twice daily
Monitor for haematological toxicity
Non-nucleoside reverse 
transcriptase inhibitor 
Nevirapine 10 mg/mL Appropriate dose for treatment of premature neonates is 
not known







80 mg/20 mg LPV/r per 1 mL Appropriate dose for treatment of premature neonates is 
not known
Contraindicated < 14 days of age and < 42  
weeks corrected gestational age. Refer to  
text for details on monitoring required
Source: Adapted from Ref. 11
Note: Zidovudine (AZT) is the only ARV drug for which dosing for treatment of premature neonates is approved. However, treatment with AZT monotherapy is not recommended. Body surface 
area (m2) = (0.05 x weight [kg]) + 0.05.
ARV, antiretroviral; LPV/r, Lopinavir/ritonavir; FDA, Food and Drug Administration.
cART, combination antiretroviral therapy; AZT, zidovudine; 3TC, Lamivudine; NVP, Nevirapine; ARV, antiretroviral; ALT, alanine aminotransferase; LPV/r, Lopinavir/ritonavir; NDOH, National 
Department of Health; PCR, polymerase chain reaction.
FIGURE 1: Recommended process for initiation of combination antiretroviral therapy in neonates. 
Neonatal cART Algorithm 
Counsel mother/ caregiver/ family
about HIV diagnosis 
Positive HIV PCR result during first 4 weeks of life
Continue or re-establish
breastfeeding if possible
Obtain expert advice for HIV-infect-
ed infants born to mothers on 2nd
or 3rd line cART
Send confirmatory viral detection assay (repeat HIV DNA PCR test or HIV RNA/Viral load),
CD4 count/percentage, full blood count/differential count, ALT, urea & creatinine.
Consider ARV drug resisitance testing (genotyping)
Is it safe to start lopinavir/ritonavir (LPV/r, Kaletra*)?
• Is the infant > 14 days of age AND >42 weeks corrected gestational age?
• Is the urea, creatinine and ALT in normal range?
NO
• If <35 weeks corrected gestational age: discuss with expert
• If ≥35 weeks corrected gestational age, regardless of postnatal age, start/switch to
   cART regimen as follows:
AZT: 4mg/kg/dose twice daily until 4 weeks of age
3TC: 2mg/kg/dose twice daily until 4 weeks of age
NVP: 6mg/kg/dose twice daily
Review 1-2 weekly for 1st 8-12 weeks on cART and check/adjust ARV doses at each visit Review 1-2 weekly for 1st 8-12 weeks on cART and check/adjust ARV doses at each visit
Monitor FBC/differential, ALT, urea & creatinine 2-4 weekly for first 12 weeks.
If abnormal, discuss with expert
Monitor FBC/differential, ALT, urea & creatinine 2-4 weekly for first 12 weeks.   
If abnormal, discuss with expert
•  At 2 weeks of age, adjust NVP dose to 200mg/m2/dose twice daily •  At 4 weeks of age,
       ◦ adjust 3TC dose to 4mg/kg/dose twice daily (if >3kg body weight, can use
           SA NDOH ARV dosing chart)
       ◦ adjust AZT dose to 12mg/kg/dose twice daily or 240mg/m2/dose twice daily
           (if >3kg body weight, can use SA NDOH ARV dosing chart)•  At 4 weeks of age,
       ◦ adjust 3TC dose to 4mg/kg/dose twice daily (if >3kg body weight, can use
           SA NDOH ARV dosing chart)
       ◦ adjust AZT dose to 12mg/kg/dose twice daily or 240mg/m2/dose twice daily
           (if >3kg body weight, can use SA NDOH ARV dosing chart)
•  Do HIV viral load at 4-6 months of age
•  Do HIV viral load at 4-6 months of age
Consider elective switch from AZT to ABC if remains virally suppressed
Consider elective switch from AZT to ABC if remains virally suppressed
Body surface area (m2) = [0.05 × weght (kg)] + 0.05
•  Once infant is > 14 days of age AND >42 weeks corrected gestational age, switch
    from NVP to LPV/r 300mg LPV/m2/dose twice daily (once infant is >3kg body weight
    and >28 days of age, can use SA NDOH ARV dosing chart)
•  Once infant is >3kg body weight and >28 days of age, can dose LPV/r, (Kaletra®)
    according to SA NDOH ARV dosing chart 
YES
Start/switch to cART regimen as follows:
AZT: 4mg/kg/dose twice daily until 4 weeks of age
3TC: 2mg/kg/dose twice daily until 4 weeks of age
Lopinavir/ritonavir: 300mg LPV/m2/dose twice daily
http://www.sajhivmed.org.za doi:10.4102/sajhivmed.v16i1.361
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If cART is initiated in premature neonates, expert guidance 
on dosing and toxicity monitoring should be obtained.
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